Feedback
Settings

Settings

Goto Application

377,421 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 37,743
1.20240245772BI-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND GENETICALLY ENGINEERED IMMUNE CELLS EXPRESSING SUCH
US - 25.07.2024
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No 18561307 Applicant Celledit LLC Inventor Biliang Hu

A bi-specific chimeric antigen receptor (bi-specific CAR) comprising a single chain variable fragment (scFv) and a single variable domain (VHH) in the extracellular antigen binding domain, wherein the scFv and VHH bind tumor associated antigens. Also provided herein are genetically engineered immune cells expressing such bi-specific CAR and therapeutic uses of the genetically engineered immune cells.

2.20240247265CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNA
US - 25.07.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 18587710 Applicant Peking University Inventor Wensheng WEI

The present application provides linear RNA precursors and constructs for preparing circular RNAs (circRNAs) comprising an effector RNA sequence, such as a coding RNA sequence. In some embodiments, the linear RNA comprises from the 5′ end to the 3′ end: (a) a first portion of an RNA element (e.g., an IRES), (b) an effector RNA sequence, and (c) a second portion of the RNA element, wherein the first and the second portions of the RNA element associate with each other to form a double-stranded region of at least 4 basepairs long, wherein the 5′ end of the first portion of the RNA element and the 3′ end of the second portion of the RNA element form a nick in the double-stranded region, and wherein an RNA ligase can ligate the nick. Also provided are methods of preparing circRNAs, circRNAs prepared thereof, and methods of using the circRNAs.

3.WO/2024/152112G PROTEIN-COUPLED RECEPTOR (GPCR) ANTIBODIES COUPLED TO HOMOLOGOUS DIMERIZATION (HD) PEPTIDES
WO - 25.07.2024
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CA2024/050046 Applicant MORGAN, Alton C. Inventor MORGAN, Alton C.
G protein-coupled receptor (GPCR) antibodies coupled to an HD peptide are disclosed, as well as methods of manufacture and uses of said antibodies. The HD peptides may comprise (i) an amino acid sequence of a naturally occurring HD peptide, or a conservative variant thereof, (ii) an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide, or a conservative variant thereof; (iii) an amino acid sequence of a naturally occurring HD peptide with one or more hydrophilic substitutions, or (iv) an HD peptide dimer.
4.WO/2024/154002GLYCOSYLATED ANIMAL PROTEIN EXPRESSION IN PLANT CELLS
WO - 25.07.2024
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/IB2024/000031 Applicant ASTERIX FOODS LTD Inventor EVEN, Dan
A method for animal protein production in a plant cell is disclosed. The method comprises designing a DNA vector for expression of an animal gene; inserting the DNA vector into the plant cell; grow the cells in defined media under defined conditions. In certain embodiments, the protein will remain in the Endoplasmic reticulum preventing downstream glycan modification. The addition of H/KDEL fused to the C-Terminal CDS of the protein will keep the protein from moving out of the endoplasmic reticulum. In some embodiments, the protein will pass from the endoplasmic reticulum to the Golgi apparatus and undergo additional modifications. In some embodiments, the addition of a vacuole targeting signal peptide fused to the C-terminal CDS of the protein directs the protein to a vacuole. In certain embodiments, the protein is passed along the endoplasmic reticulum, the Golgi apparatus, and undergo further modifications in the apoplast.
5.WO/2024/152937GENE EDITING SYSTEM TARGETING FGF2 AND USE THEREOF
WO - 25.07.2024
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/CN2024/071176 Applicant GUANGZHOU REFORGENE MEDICINE CO., LTD. Inventor LIANG, Junbin
An FGF2 RNA inhibitor and the use thereof. The inhibitor is a gene editing system. The gene editing system can be used in the knockdown of FGF2 RNA and can be used for treating age-related macular degeneration, achondroplasia and cancers (such as urothelial carcinoma, breast cancer, endometrial cancer, squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, gastric and gastroesophageal junction cancer, pulmonary fibrosis, mesothelioma, cholangiocarcinoma, cholangiocellular carcinoma and intrahepatic cholangiocarcinoma).
6.WO/2024/152787LONG-ACTING INSULIN-FC FUSION PROTEIN
WO - 25.07.2024
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2023/137326 Applicant SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Inventor WANG, Chunhe
The present invention provides a long-acting insulin-Fc fusion protein. The insulin-Fc fusion protein of the present invention has reduced insulin receptor affinity, improved selectivity to auxin receptors, and a prolonged half-life in vivo, and can prolong a glucose lowering duration in vivo, reduce the time interval of insulin usage, and reduce the side effects such as a hypoglycemia risk.
7.WO/2024/152862SINV VECTOR EXPRESSING IL-12 AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUG
WO - 25.07.2024
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
 Appl.No PCT/CN2023/142504 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor JIA, Fan
Provided are a SINV vector expressing IL-12 and the use thereof in the preparation of an anti-tumor drug. The vector uses pSINV as a framework vector, and the framework vector is connected to IL-12, specifically, the vector is connected to a UBC promoter, 5’UTR, a nucleotide sequence of an NSP1 gene, a nucleotide sequence of an NSP2 gene, a nucleotide sequence of an NSP3 gene, a nucleotide sequence of an NSP4 gene, a 26s promoter, a nucleotide sequence of a CAP gene, a nucleotide sequence of an E3 gene, a nucleotide sequence of an E2 gene, a nucleotide sequence of a 6K gene, a nucleotide sequence of an E1 gene, a 26s promoter, a nucleotide sequence of an IL-12 gene, and 3’UTR; and the nucleotide sequence of the SINV infectious vector is as shown in SEQ ID NO. 7.
8.WO/2024/155727SYSTEMS AND METHODS FOR TARGETED CONTINUOUS GENOME MUTAGENESIS
WO - 25.07.2024
Int.Class A01K 67/0275
Appl.No PCT/US2024/011869 Applicant THE BROAD INSTITUTE, INC. Inventor CHEN, Fei
The invention provides for compositions, systems, and methods for long-range targeted mutagenesis. In particular, the invention provides engineered compositions comprising a programmable nickase configured to introduce a single-strand nick in double-stranded DNA (dsDNA) at one or more targeted nick sites; a helicase configured to unwind a portion of the dsDNA at the one or more targeted nick sites; and a deaminase configured to introduce one or more base edits within the portion of unwound dsDNA. Also provided are vector and delivery systems comprising one or more polynucleotides encoding the components of the compositions, as well as modified cells, cell populations, animal models, pharmaceutical compositions, and kits comprising the compositions.
9.WO/2024/156012COMPOSITIONS AND METHODS FOR ENHANCED DRUG LOADING INTO LIPID-BASED CARRIERS
WO - 25.07.2024
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
 Appl.No PCT/US2024/017222 Applicant UNIVERSITY OF NOTRE DAME DU LAC Inventor WANG, Yichun
Described herein are compositions and methods for enhanced drug loading into lipid-based carriers. The compositions and methods may comprise a drug-bound chiral graphene quantum dot comprising a graphene quantum dot functionalized with a non-aromatic chiral ligand having a single chiral center, wherein a chirality of the chiral graphene quantum dot matches a chirality of a lipid content of the lipid-based carrier. The drug-bound chiral graphene quantum dot permeates into the lipid-based carrier via matching of the chirality of the chiral graphene quantum dot to the chirality of the lipid content of the lipid-based carrier to load the drug into the lipid-based carrier. The compositions and methods achieve a drug loading efficiency of greater than 60% into lipid-based carriers.
10.20240247264NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
US - 25.07.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 18564201 Applicant CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.) Inventor Thierry PEDRAZZINI

This invention generally relates to methods for treating and/or preventing a cardiac pathology in a subject, comprising administering to said subject an effective amount of a modulator of FIXER, a novel lncRNA controlling cardiac fibrosis and remodeling following injury in the heart. The invention also provides methods for diagnosing cardiac pathologies in a subject based on FIXER expression in cardiac tissues or in body fluids.

# -